Takeda wins long-awaited US approval for first oral drug for eosinophilic esophagitis

The FDA today approved Takeda’s Eohilia, the first oral drug for patients with eosinophilic esophagitis (EoE) in the US, which the company briefly abandoned after receiving a complete response letter.

Takeda will now have to compete with Sanofi and Regeneron’s blockbuster Dupixent, which won its expanded approval…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks